| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.35 | $70.63 (0%) | 🛒 Add to cart |
| 60 | $1.72 | $141.27 $102.92 (27%) | 🛒 Add to cart |
| 90 | $1.51 | $211.90 $136.22 (36%) | 🛒 Add to cart |
| 120 | $1.40 | $282.54 $167.51 (41%) | 🛒 Add to cart |
| 180 | $1.30 | $423.81 $234.10 (45%) | 🛒 Add to cart |
| 270 | $1.23 | $635.71 $331.98 (48%) | 🛒 Add to cart |
| 360 | $1.19
Best per pill | $847.62 $427.85 (50%) | 🛒 Add to cart |
Synonyms | |||
More info:
lopid
Gemfibrozil, marketed under the brand name Lopid among others, is a fibrate-class medication primarily prescribed for managing specific dyslipidemias. It’s not a dietary supplement or medical device but a prescription drug that requires careful clinical oversight. This review will cover its pharmacological profile, clinical applications, and practical considerations based on current evidence and real-world use. Lopid: Effective Lipid Management for Hypertriglyceridemia - Evidence-Based Review 1. Introduction: What is Lopid? Its Role in Modern Medicine Lopid contains the active pharmaceutical ingredient gemfibrozil, which belongs to the fibrate class of drugs.
Aciphex: Potent Acid Suppression for GERD and Ulcer Healing - Evidence-Based Review
Rabeprazole sodium, marketed under the brand name Aciphex, represents a significant advancement in the proton pump inhibitor (PPI) class of medications. It’s specifically engineered to suppress gastric acid secretion by targeting the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Unlike earlier acid-suppressing agents, Aciphex provides more consistent and prolonged acid control, making it particularly valuable for managing various acid-related disorders. Its development addressed the need for faster onset of action and more predictable pharmacokinetics across different patient populations, including those with CYP2C19 genetic polymorphisms that affect metabolism of other PPIs.
aggrenox
Aggrenox is a combination medication containing 200mg of extended-release dipyridamole and 25mg of aspirin, specifically formulated for secondary stroke prevention. It represents one of the more sophisticated approaches to cerebrovascular protection, essentially combining two antiplatelet mechanisms in a single pill. What’s interesting is how this combination emerged from the understanding that single antiplatelet therapy often falls short in high-risk patients. Aggrenox: Comprehensive Stroke Prevention Through Dual Antiplatelet Action 1. Introduction: What is Aggrenox?
Amalaki: Comprehensive Cellular Protection and Systemic Rejuvenation - Evidence-Based Review
Amalaki, derived from the fruit of the Phyllanthus emblica tree, also known as Indian gooseberry, is a cornerstone of Ayurvedic medicine with a documented history spanning over 3,000 years. Classified as a potent rasayana (rejuvenator), it is revered for its extensive therapeutic profile, primarily attributed to its exceptionally high concentration of vitamin C and a unique profile of bioactive compounds like emblicanin A and B, which are powerful antioxidants. In modern integrative medicine, amalaki is increasingly recognized not merely as a simple supplement but as a complex phytotherapeutic agent with systemic benefits, supported by a growing body of preclinical and clinical research.
Bupron SR: Sustained Mood Stabilization and Smoking Cessation Aid - Evidence-Based Review
Bupron SR is a sustained-release formulation of bupropion hydrochloride, primarily indicated for the management of major depressive disorder and as an aid to smoking cessation treatment. Unlike immediate-release formulations, this extended-release delivery system maintains more consistent plasma concentrations over a 24-hour period, potentially reducing peak-related side effects while maintaining therapeutic efficacy. The SR designation indicates this modified-release characteristic, which represents a significant advancement in antidepressant delivery systems. 1. Introduction: What is Bupron SR?
bupropion
Bupropion is an atypical antidepressant belonging to the norepinephrine-dopamine reuptake inhibitor (NDRI) class, distinct from the more common SSRIs. Initially approved for depression in 1985, it’s become a cornerstone treatment for major depressive disorder and smoking cessation, with off-label uses expanding to ADHD and sexual dysfunction caused by other antidepressants. Its unique mechanism avoids serotonin pathways, which explains its different side effect profile - no sexual dysfunction or weight gain typically, but higher seizure risk at higher doses.
Cepmox: Comprehensive Digestive and Systemic Support - Evidence-Based Review
Product Description Cepmox represents a novel class of broad-spectrum enzymatic digestive support complexes, specifically engineered for patients with compromised gut integrity and systemic inflammation. Unlike conventional single-enzyme formulations, Cepmox utilizes a patented dual-phase delivery system combining serrapeptase and nattokinase in enteric-coated capsules, allowing for targeted release in both the small intestine and systemic circulation. We initially developed it for post-surgical adhesion prevention, but the clinical applications have expanded dramatically. I remember our first prototype failing miserably because we used standard gelatin capsules—the enzymes were completely deactivated in gastric acid.
contrave
Contrave represents one of the more interesting pharmacological approaches to weight management we’ve seen in recent years—essentially a combination of two older medications, naltrexone and bupropion, packaged specifically for chronic weight management. What’s fascinating is how it leverages known neurobiological pathways rather than inventing completely new mechanisms. I remember when the clinical trial data first crossed my desk back in 2014, my initial skepticism was tempered by the clever dual-mechanism approach targeting both the reward system and hunger signaling.
dipyridamole
Dipyridamole is a fascinating pharmaceutical agent with a complex dual identity - originally developed as a coronary vasodilator but finding its most significant clinical application in antiplatelet therapy. What makes dipyridamole particularly interesting is how its mechanism differs fundamentally from other antiplatelet agents like aspirin or clopidogrel. Rather than directly inhibiting cyclooxygenase or P2Y12 receptors, dipyridamole works through adenosine-mediated pathways and phosphodiesterase inhibition, creating this unique dual-action profile that’s made it particularly valuable in specific clinical scenarios.
